




# INDIANA & FRANCE

A deep and mutually beneficial relationship

**SOUTH WEST CHICAGO & SOUTH BEND AREA**



**GREATER FORT WAYNE AREA**

**GREATER INDIANAPOLIS AREA**

JOBS

FRENCH FIRMS ACCOUNT FOR  
**15.3%**  
OF JOBS CREATED BY FOREIGN COMPANIES

**33,400**  
JOBS CREATED BY FRENCH COMPANIES

**#2**  
FRANCE'S RANK FOR JOB CREATION

**+126%**  
GROWTH OVER 10 YEARS

## Orano Med

Orano Med has achieved a major milestone with the inauguration of its ATLab facility in Indianapolis, Indiana; the world's first industrial-scale pharmaceutical laboratory dedicated to the production of lead-212 radioligand therapies. This state-of-the-art facility, spanning over 30,000 square feet, represents a \$20 million investment. Targeted Alpha Therapy with lead-212 combines the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of lead-212 generated alpha emissions. The construction of Orano Med's ATLab Indianapolis is therefore a major step towards making these promising new treatments available to cancer patients with high unmet needs in North America.

Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company developing a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Orano Med has 212Pb production facilities, laboratories and R&D centers in France and the United States.

TRADE

**\$3,360 MILLION**  
TRADED ANNUALLY

### EXPORTS TO FRANCE \$1,423 MILLION



### IMPORTS FROM FRANCE \$1,937 MILLION

